|
Sep 19
|
Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease
|
|
Aug 19
|
Tiziana Life Sciences Appoints New Chief Executive Officer
|
|
Aug 14
|
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
|
|
Jul 24
|
Tiziana Life Sciences Granted FDA Fast Track Designation
|
|
Jun 28
|
Tiziana Receives $3.4 Million in Non-Dilutive Funding
|
|
Jun 26
|
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab
|
|
Jun 11
|
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
|
|
May 13
|
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
|
|
Apr 25
|
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
|
|
Apr 23
|
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
|
|
Apr 22
|
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
|
|
Apr 19
|
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
|
|
Apr 18
|
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
|
|
Apr 11
|
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
|
|
Mar 5
|
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
|
|
Jan 9
|
TLSA: First Phase II SPMS Patient Dosed
|
|
Dec 4
|
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
|
|
Nov 30
|
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
|
|
Sep 8
|
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
|
|
Sep 6
|
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
|